The emergence of targeted therapy for patients with hematological diseases has permanently altered the therapeutic landscape. Immunochemotherapy regimes are now more and more being replaced by targeted therapies due to superior efficacy and better safety profiles. However, evolution and selection of subclones with continuous treatment leads to disease relapse and resistance toward these novel drugs.
View Article and Find Full Text PDFRobotically Assisted Minimally Invasive Surgery (RAMIS) offers many advantages over manual surgical techniques. Most of the limitations of RAMIS stem from its non-intuitive user interface and costs. One way to mitigate some of the limitations is to automate surgical subtasks (e.
View Article and Find Full Text PDF